Myriad Genetics (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, has entered into a strategic collaboration with PATHOMIQ, an innovator in AI-enabled prognostic and predictive testing. Under this agreement, Myriad will exclusively license PATHOMIQ_PRAD, PATHOMIQ’s AI-powered platform for prostate cancer diagnostics, in the United States.
George Daneker, Jr., MD, President and Chief Clinical Officer of Oncology at Myriad Genetics, stated that integrating AI and molecular insights will enhance decision-making across the patient journey. He explained that combining genetic and morphological data with AI-driven predictions allows clinicians to better assess disease progression and treatment options for prostate cancer patients.
PATHOMIQ’s AI platform is designed to decode complex morphological structures in cancer pathology, enabling rapid and precise assessments of patient outcomes, treatment responses, and genotype mutations. Ashutosh K. Tewari, Chairman of the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai, noted that the PATHOMIQ_PRAD model demonstrated high prediction accuracy and outperformed conventional markers in identifying high-risk patients likely to experience early metastasis post-radical prostatectomy.
Myriad Genetics will expand its prostate cancer testing portfolio with this technology, offering AI-enhanced solutions for treatment decisions both at the time of biopsy for active surveillance and post-surgical or radiation therapy. Rajat Roy, CEO and co-founder of PATHOMIQ, emphasized that this collaboration represents a step forward in personalized medicine by improving patient outcomes through AI-driven diagnostics.
Paul J. Diaz, President and CEO of Myriad Genetics, highlighted that the partnership aligns with Myriad’s commitment to leveraging AI and machine learning to enhance the speed, accuracy, and affordability of diagnostic solutions. He stated that PATHOMIQ’s platform, combined with Myriad’s expertise and market reach, will bring next-generation AI-powered cancer diagnostics to clinicians and patients nationwide.
Myriad expects to commercially launch its first AI-driven prostate cancer clinical test later this year.
